Key points are not available for this paper at this time.
The main treatment for renal anemia is subcutaneous injection of recombinant human erythropoietin (rHuEPO) However, this may be complicated by anti-EPO antibody-mediated pure red cell aplasia (PRCA) PRCA responds poorly to immunosuppressive therapy and requires long-term reliance on blood cell transfusion Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. We report one case in which roxadustat successfully improved anti-EPO antibody-mediated PRCA.
Xu et al. (Tue,) studied this question.